Project Grant R21CA301170
- Federal Grant Award Summary New York University School of Medicine received a $716,681 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective May 22, 2026 through April 30, 2031. This award supports fundamental research aimed at understanding and developing therapeutic interventions for myeloid sarcoma (MS), a rare extramedullary subtype of acute myeloid leukemia affecting approximately 5-10% of AML patients. The research...
- Federal Grant Award Summary New York University School of Medicine received a $585,482 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective June 1, 2026 through May 31, 2031. This five-year research award supports fundamental investigations into the molecular mechanisms of breast cancer metastasis, specifically examining the dual role of the translation factor DAP5 (Death-Associated Protein 5) in selective messenger RNA...
- Federal Grant Award Summary Health Research, Inc. (operating as Health Research at Roswell Park) received a $173,500 Project Grant awarded August 7, 2025, by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to conduct a correlative clinical study investigating the effects of CXCR1/2 inhibition on the immune microenvironment of multiple myeloma patients. The research leverages preliminary findings demonstrating significant accumulation of CXCR2-positive...
- Federal Project Grant Award Summary New York University School of Medicine received a $695,852 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded on May 1, 2026, with a completion date of April 30, 2031. The award funds fundamental research investigating T cell circuits in the lymphatic system during melanoma progression, specifically examining tumor-draining lymph nodes (TDLNs) as key immune surveillance hubs. The research...
- Federal Grant Award Summary New York University School of Medicine received a $714,110 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), effective September 1, 2025, through August 31, 2030. The award supports research titled "Translating Insights in Follicular Lymphoma for Improved Diagnosis and Classification," which aims to develop and validate predictive biomarkers for risk stratification in...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- Federal Project Grant Award Summary Mayo Clinic received a $558,016 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) awarded May 8, 2026, with completion targeted for April 30, 2031. The project investigates accelerated biological aging and immunosenescence as drivers of racial disparities in Monoclonal Gammopathy of Undetermined Significance (MGUS) and Multiple Myeloma (MM). The research aims to understand why African American...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a $452,540 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on July 11, 2025, with a completion date of June 30, 2027. This award supports the development of a novel T-cell imaging paradigm utilizing positron emission tomography (PET) agents targeting CD8 and CD4 markers to provide real-time monitoring of endogenous T-cell trafficking, tumor...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded New York University School of Medicine a $2,013,199 Project Grant effective September 1, 2025, through November 30, 2029, under the Cancer Treatment Research program (CFDA 93.395). This award supports the expansion of NCI-sponsored clinical research in hematologic malignancies to Brooklyn and Queens through the Perlmutter Cancer Center (PCC). The PCC will oversee a robust portfolio of clinical trials across national networks...
- Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $2.5M Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded June 1, 2026, with completion scheduled for May 31, 2031. This five-year Program Project (P01) grant funds integrated research to identify genetic and immunological mechanisms driving malignant transformation from Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple...
New York University School of Medicine received a $466,125 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), awarded May 14, 2026, with completion targeted for April 30, 2028. The grant funds fundamental research investigating the role of incretin mimetics in reducing the risk of development and progression of multiple myeloma (MM) and its precursor condition, monoclonal gammopathy of undetermined significance (MGUS). This research addresses a significant clinical need, as MGUS affects approximately 5% of individuals over age 70, with roughly 1% annual transformation risk to MM, yet currently no therapeutic interventions are offered to MGUS patients beyond close monitoring. The research project utilizes two murine disease models to determine whether weight loss alone and/or treatment with incretin mimetics can reduce MM disease incidence and burden. One model examines disease development contingent upon high-fat diet conditions, while the other investigates disease progression independent of diet and weight. The study seeks to establish mechanistic relationships between obesity, bone marrow adipocytes, the permissive bone marrow microenvironment, and clonal cell proliferation—with the ultimate objective of translating findings into preventive strategies that could decrease MM progression risk, reduce MGUS incidence, and lower the overall population burden of plasma cell dyscrasias.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $466.1k | 5/22/26 |